Sangamo is pioneering the future of genomic medicine
Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. We have a robust preclinical pipeline with programs in emerging areas that could provide value in the mid-to-long term. Our goal is to develop a wholly owned genomic medicine portfolio, which we fund via our collaborations with blue-chip biopharmaceutical partners, which have already brought in $815M in upfronts and milestones with billions in potential milestone payments. We believe that manufacturing is a strategic advantage and gives us greater control over timelines, quality and supply. Our ability to fund our projects enables us to execute and deliver on our mission.
Data Provided by Refinitiv. Minimum 15 minutes delayed.

-
November 16, 2022
Brisbane, California, November 16, 2022 – Dosing has resumed in the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A. Dosing resumed on November 10, 2022.
-
November 3, 2022
Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 3, 2022-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results.
-
October 27, 2022
BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 27, 2022-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to release its third quarter 2022 financial results after the market closes on Thursday, November 3, 2022 .
-
October 12, 2022
- Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across four dose cohorts in the nine treated patients in the dose escalation phase. - All nine patients exhibited elevated α-Gal A activity, ranging from nearly 2-fold to 30-fold of mean normal, for up to 23 months
Filing date | Form | Description | Filing Group | View |
---|---|---|---|---|
PRE 14A | A preliminary proxy statement providing notification matters to be brought to a vote |
Proxy Filings
|
View HTML | |
PRE 14A | A preliminary proxy statement providing notification matters to be brought to a vote |
Proxy Filings
|
View HTML | |
PRE 14A | A preliminary proxy statement providing notification matters to be brought to a vote |
Proxy Filings
|
View HTML |
- More events are coming soon.
-
Dec 12, 2022
-
Dec 1, 2022 at 10:30 AM EST